Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 309491, 10 pages
http://dx.doi.org/10.1155/2015/309491
Clinical Study

Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia

1Hospital Infantil de México Federico Gómez, Department of Hematology and Oncology, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico
2Hospital Infantil de México Federico Gómez, Research Division, Calle Doctor Márquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 Mexico City, DF, Mexico

Received 15 May 2014; Revised 2 September 2014; Accepted 10 September 2014

Academic Editor: Juan Manuel Mejía-Aranguré

Copyright © 2015 Aurora Medina-Sanson et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. J. L. Kaspers and U. Creutzig, “Pediatric acute myeloid leukemia: international progress and future directions,” Leukemia, vol. 19, no. 12, pp. 2025–2029, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. B. J. Lange, F. O. Smith, J. Feusner et al., “Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group,” Blood, vol. 111, no. 3, pp. 1044–1053, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. O. Lie, J. Abrahamsson, N. Clausen et al., “Long-term results in children with AML: NOPHO-AML Study Group—report of three consecutive trials,” Leukemia, vol. 19, no. 12, pp. 2090–2100, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Abrahamsson, E. Forestier, J. Heldrup et al., “Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate,” Journal of Clinical Oncology, vol. 29, no. 3, pp. 310–315, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Creutzig, J. Ritter, M. Zimmermann et al., “Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of study acute myeloid Leukemia-Berlin-Frankfurt-Münster 93,” Journal of Clinical Oncology, vol. 19, no. 10, pp. 2705–2713, 2001. View at Google Scholar · View at Scopus
  6. R. F. Stevens, I. M. Hann, K. Wheatley, and R. G. Gray, “Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council's 10th AML trial,” British Journal of Haematology, vol. 101, no. 1, pp. 130–140, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. J. J. Wang, O. S. Selawry, T. J. Vietti, and G. P. Bodey, “Prolonged infusion of arabinosyl cytosine in childhood leukemia,” Cancer, vol. 25, no. 1, pp. 1–6, 1970. View at Google Scholar · View at Scopus
  8. C. E. Cass, J. D. Young, and S. A. Baldwin, “Recent advances in the molecular biology of nucleoside transporters of mammalian cells,” Biochemistry and Cell Biology, vol. 76, no. 5, pp. 761–770, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. W. S. Ronald, M. L. den Boer, J. P. P. Meijerink et al., “Differential mRNA expression of Ara -C metabolizing enzymes explain Ara -C sensitivity in MLL gene- rearrengements infant acute lymphoblastic leukemia,” Blood, vol. 101, pp. 1270–1276, 2003. View at Publisher · View at Google Scholar
  10. W. Plunkett, J. O. Liliemark, E. Estey, and M. J. Keating, “Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C,” Seminars in Oncology, vol. 14, no. 2, pp. 159–166, 1987. View at Google Scholar · View at Scopus
  11. P. P. Major, E. M. Egan, G. G. Beardsley, M. D. Minden, and D. W. Kufe, “Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, pp. 3235–3239, 1981. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Dumontet, K. Fabianowska-Majewska, D. Mantincic et al., “Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562,” British Journal of Haematology, vol. 106, no. 1, pp. 78–85, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Cros, L. Jordheim, C. Dumontet, and C. M. Galmarini, “Problems related to resistance to cytarabine in acute myeloid leukemia,” Leukemia & Lymphoma, vol. 45, no. 6, pp. 1123–1132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. R. L. Momparler and G. A. Fischer, “Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside,” The Journal of Biological Chemistry, vol. 243, no. 16, pp. 4298–4304, 1968. View at Google Scholar · View at Scopus
  15. L. Yue, Y. Saikawa, K. Ota et al., “A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity,” Pharmacogenetics, vol. 13, no. 1, pp. 29–38, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Gilbert, O. E. Salavaggione, Y. Ji et al., “Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics,” Clinical Cancer Research, vol. 12, no. 6, pp. 1794–1803, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. N. A. Kocabas, P. Aksoy, L. L. Pelleymounter et al., “Gemcitabine pharmacogenomics: deoxycytidine Kinase (DCK) and cytidylate kinase (CMPK) gene resequencing and functional genomics,” Drug Metabolism and Disposition, vol. 36, no. 9, pp. 1951–1959, 2008. View at Publisher · View at Google Scholar
  18. P.-P. Xu, B.-A. Chen, J.-F. Feng et al., “Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia,” Chinese Medical Journal, vol. 125, no. 12, pp. 2137–2143, 2012. View at Google Scholar · View at Scopus
  19. D. Bhatla, R. B. Gerbing, T. A. Alonzo et al., “Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia,” British Journal of Haematology, vol. 144, no. 3, pp. 388–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. M. Galmarini, X. Thomas, K. Graham et al., “Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine,” British Journal of Haematology, vol. 122, no. 1, pp. 53–60, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. E. Szantai, Z. Ronai, M. Sasvari-Szekely, G. Bonn, and A. Guttman, “Multicapillary electrophoresis analysis of single-nucleotide sequence variations in the deoxycytidine kinase gene,” Clinical Chemistry, vol. 52, no. 9, pp. 1756–1762, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. F. M. Carpi, S. Vincenzetti, D. Micozzi, A. Vita, and V. Napolioni, “PCR-based methods for CDA K27Q and A70T genotyping: genotypes and alleles distribution in a central Italy population,” Molecular Biology Reports, vol. 37, no. 7, pp. 3363–3368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Hubeek, R. W. Stam, G. J. Peters et al., “The human equilibrative nucleoside transporter I mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia,” British Journal of Cancer, vol. 93, no. 12, pp. 1388–1394, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Gupta, M. Bonilla, P. Valverde et al., “Treatment-related mortality in children with acute myeloid leukaemia in Central America: incidence, timing and predictors,” European Journal of Cancer, vol. 48, no. 9, pp. 1363–1369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. J.-Y. Shi, Z.-Z. Shi, S.-J. Zhang et al., “Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients,” Pharmacogenetics, vol. 14, no. 11, pp. 759–768, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Joerger, T. M. Bosch, V. D. Doodeman, J. H. Beijnen, P. H. M. Smits, and J. H. M. Schellens, “Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers,” European Journal of Clinical Pharmacology, vol. 62, no. 8, pp. 681–684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. C. D. Steuart and P. J. Burke, “Cytidine deaminase and the development of resistance to arabinosyl cytosine,” Nature: New biology, vol. 233, no. 38, pp. 109–110, 1971. View at Google Scholar · View at Scopus
  28. J. K. Schröder, C. Kirch, S. Seeber, and J. Schütte, “Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia,” British Journal of Haematology, vol. 103, no. 4, pp. 1096–1103, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. F. M. Carpi, S. Vincenzetti, J. Ubaldi et al., “CDA gene polymorphisms and enzyme activity: genotype-phenotype relationship in an Italian-Caucasian population,” The American Journal of Hematology, vol. 88, pp. 1001–1006, 2013. View at Publisher · View at Google Scholar
  30. S. Parmar, A. Seeringer, D. Denich et al., “Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells,” Pharmacogenomics, vol. 12, no. 4, pp. 503–514, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Banklaui, S. Jindadamrongwech, R. Sawangpanich et al., “Effect of genetic alterations of cytarabine-metabolizing enzymes in childhood acute lymphoblastic leukemia,” Hematology/Oncology and Stem Cell Therapy, vol. 3, no. 3, pp. 103–108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Estey, W. Plunkett, D. Dixon, M. Keating, K. McCredie, and E. J. Freireich, “Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia,” Leukemia, vol. 1, no. 8, pp. 580–583, 1987. View at Google Scholar · View at Scopus
  33. J. E. Rubnitz, S. Pounds, X. Cao et al., “Treatment outcome in older patients with childhood acute myeloid leukemia,” Cancer, vol. 118, no. 24, pp. 6253–6259, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. P. Jordheim, T. Nguyen-Dumont, X. Thomas, C. Dumontet, and S. V. Tavtigian, “Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53,” Drug Metabolism and Disposition, vol. 36, no. 12, pp. 2419–2423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. U. Mahlknecht, C.-L. Dransfeld, N. Bulut et al., “SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival,” Leukemia, vol. 23, no. 10, pp. 1929–1932, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Tibaldi, E. Giovannetti, E. Vasile et al., “Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients,” Clinical Cancer Research, vol. 14, no. 6, pp. 1797–1803, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Sugiyama, S.-J. Lee, S. S. Lee et al., “Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene,” Drug Metabolism and Pharmacokinetics, vol. 24, no. 6, pp. 553–556, 2009. View at Publisher · View at Google Scholar · View at Scopus